112 related articles for article (PubMed ID: 2403803)
21. Therapeutic strategies for B cell malignancies involving idiotype-anti-idiotype interactions.
Stevenson FK; Stevenson GT
Int Rev Immunol; 1986 Jul; 1(3-4):303-33. PubMed ID: 3334051
[TBL] [Abstract][Full Text] [Related]
22. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
[TBL] [Abstract][Full Text] [Related]
23. Expression of immunoglobulin-cross-reactive molecules by neoplastic human T cells. I. Surface detection and isolation of molecules reactive with chicken anti-F(ab')2, anti-alpha and anti-mu antibodies.
Haegert DG; Timm M
Immunology; 1983 Nov; 50(3):447-59. PubMed ID: 6195097
[TBL] [Abstract][Full Text] [Related]
24. Anti-idiotypic DNA vaccines for lymphoma immunotherapy require the presence of both variable region genes for tumor protection.
Benvenuti F; Burrone OR; Efremov DG
Gene Ther; 2000 Apr; 7(7):605-11. PubMed ID: 10819576
[TBL] [Abstract][Full Text] [Related]
25. Anti-CD45 and anti-CD52 (Campath) monoclonal antibodies effectively eliminate systematically disseminated human non-Hodgkin's lymphoma B cells in Scid mice.
de Kroon JF; de Paus RA; Kluin-Nelemans HC; Kluin PM; van Bergen CA; Munro AJ; Hale G; Willemze R; Falkenburg JH
Exp Hematol; 1996 Jul; 24(8):919-26. PubMed ID: 8690051
[TBL] [Abstract][Full Text] [Related]
26. Idiotypic vaccination as a treatment for a B cell lymphoma.
George AJ; Folkard SG; Hamblin TJ; Stevenson FK
J Immunol; 1988 Sep; 141(6):2168-74. PubMed ID: 3049800
[TBL] [Abstract][Full Text] [Related]
27. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential.
Epstein AL; Marder RJ; Winter JN; Stathopoulos E; Chen FM; Parker JW; Taylor CR
Cancer Res; 1987 Feb; 47(3):830-40. PubMed ID: 3542194
[TBL] [Abstract][Full Text] [Related]
28. Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma.
Barrios Y; Cabrera R; Yáñez R; Briz M; Plaza A; Forés R; Fernández MN; Díaz-Espada F
Haematologica; 2002 Apr; 87(4):400-7. PubMed ID: 11940484
[TBL] [Abstract][Full Text] [Related]
29. Induction of humoral and cellular anti-idiotypic immunity by intradermal injection of naked DNA encoding a human variable region gene sequence of an immunoglobulin heavy chain in a B cell malignancy.
Abe A; Emi N; Taji H; Kasai M; Kohno A; Saito H
Gene Ther; 1996 Nov; 3(11):988-93. PubMed ID: 8940639
[TBL] [Abstract][Full Text] [Related]
30. Regulation of an idiotype+ B cell lymphoma. Effects of antigen and anti-idiotopic antibodies on proliferation and Ig secretion.
Ward RE; McNamara-Ward M; Webb CF; Altman D; Lim PL; Tucker PW; Kohler H
J Immunol; 1988 Jul; 141(1):340-6. PubMed ID: 3259969
[TBL] [Abstract][Full Text] [Related]
31. Involvement of innate and induced anti-idiotypic mechanisms in suppression of B cell tumors.
Stevenson FK; George AJ; Tutt AL; Glennie MJ; Stevenson GT
Monogr Allergy; 1987; 22():184-93. PubMed ID: 3501833
[No Abstract] [Full Text] [Related]
32. Specific enhancement of the therapeutic effect of anti-idiotype antibodies on a murine B cell lymphoma by IL-2.
Berinstein N; Starnes CO; Levy R
J Immunol; 1988 Apr; 140(8):2839-45. PubMed ID: 3258621
[TBL] [Abstract][Full Text] [Related]
33. Anti-idiotype antibodies reveal the existence of somatic mutation in human B cell lymphoma.
Levy R; Levy S; Brown SL; Kon S; Carroll W
Monogr Allergy; 1987; 22():194-203. PubMed ID: 3325832
[No Abstract] [Full Text] [Related]
34. Anti-idiotypic antibodies induced by genetic immunisation are directed exclusively against combined V(L)/V(H) determinants.
Benvenuti F; Burrone OR
Gene Ther; 2001 Oct; 8(20):1555-61. PubMed ID: 11704816
[TBL] [Abstract][Full Text] [Related]
35. Lymphoma models for B cell activation and tolerance. VI. Reversal of anti-Ig-mediated negative signaling by T cell-derived lymphokines.
Scott DW; O'Garra A; Warren D; Klaus GG
J Immunol; 1987 Dec; 139(12):3924-9. PubMed ID: 3500976
[TBL] [Abstract][Full Text] [Related]
36. Idiotypic determinants on the surface immunoglobulin of neoplastic lymphocytes: a therapeutic target.
Stevenson GT; Elliott EV; Stevenson FK
Fed Proc; 1977 Aug; 36(9):2268-71. PubMed ID: 69552
[No Abstract] [Full Text] [Related]
37. Idiotype and antigen-specific T cell responses in mice on immunization with antigen, antibody, and anti-idiotypic antibody.
Mitra-Kaushik S; Shaila MS; Karande AK; Nayak R
Cell Immunol; 2001 May; 209(2):109-19. PubMed ID: 11446743
[TBL] [Abstract][Full Text] [Related]
38. T cell development in B cell deficient mice. III. Restriction specificity of suppressor T cell factor(s) produced in mice treated chronically with rabbit anti-mouse mu chain antibody.
HayGlass KT; Naides SJ; Benacerraf B; Sy MS
J Mol Cell Immunol; 1985; 2(2):107-17. PubMed ID: 2978459
[TBL] [Abstract][Full Text] [Related]
39. Clinical evidence that the human monoclonal anti-idiotypic antibody 105AD7, delays tumor growth by stimulating anti-tumor T-cell responses.
Buckley DT; Robins AR; Durrant LG
Hum Antibodies Hybridomas; 1995; 6(2):68-72. PubMed ID: 7492753
[TBL] [Abstract][Full Text] [Related]
40. Idiotypic intramolecular help. Induction of tumor-specific antibodies by monoclonal anti-idiotypic antibody with the help of Fc-specific T helper clones.
Saeki Y; Chen JJ; Shi LF; Kohler H
J Immunol; 1989 Apr; 142(8):2629-34. PubMed ID: 2522964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
